视网膜生物製剂市场 - 按药物类别适应症、配销通路、全球预测

在视网膜疾病盛行率不断上升的推动下，2024-2032 年视网膜生物製品市场规模将以 8.2% 的复合年增长率成长。据 Oural Therapeutix 称，全球估计有 4.016 亿人受到各种形式的视网膜疾病的影响。老年性黄斑部病变 (AMD)、糖尿病视网膜病变和视网膜静脉阻塞等疾病正变得越来越常见，这主要是由于全球人口老化以及糖尿病和高血压发病率的上升。视网膜生物製剂以其先进的治疗能力提供了有针对性和有效的治疗选择。

生物技术的创新使得能够创造出专门针对视网膜疾病根本原因的新型治疗方法。与传统疗法相比，这些新的生物疗法提供了更高的疗效和安全性，为患有糖尿病视网膜病变等疾病的患者带来了显着的益处。正在进行的研究和临床试验继续解决未满足的医疗需求并扩大治疗领域。

视网膜生物製品产业根据药品类别、适应症、配销通路和地区进行分类。

TNF-a 抑制剂部分将在 2032 年获得关注，因为它们透过阻断肿瘤坏死因子-α (TNF-a) 蛋白发挥作用。这些抑制剂在减少发炎和阻止糖尿病视网膜病变和葡萄膜炎等疾病的进展方面显示出显着的功效。 TNF-a 抑制剂在保护视力和防止进一步视网膜损伤方面的有效性使其成为视网膜疾病治疗手段的宝贵补充。

到 2032 年，线上药局市场将快速成长，因为人们可以轻鬆获得各种生物疗法药物，包括治疗视网膜疾病的药物，而且价格往往具有竞争力。送货上门的便利性，加上线上咨询医疗保健专业人员的能力，使得网路药局成为对病人有吸引力的选择。 COVID-19 大流行加速了向线上购买的转变，许多患者选择数位管道以避免亲自去药局。随着越来越多的消费者习惯线上购物以满足他们的医疗保健需求，这一趋势预计将持续下去。

在完善的医疗基础设施和高额医疗支出的推动下，欧洲视网膜生物製品市场规模将在 2032 年之前稳步扩张。该地区人口老化导致视网膜疾病盛行率不断上升，对有效治疗产生了巨大需求。德国、英国、法国和义大利等国家在采用先进视网膜生物製剂方面处于领先地位，并得到强有力的监管框架和旨在改善眼睛健康的政府倡议的支持。此外，欧洲拥有多家领先的製药公司和研究机构，积极参与视网膜生物製剂的开发和商业化。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 视网膜疾病盛行率增加
    • 与视网膜生物製剂相关的研发活动不断增加
    • 生物疗法的进展
  • 产业陷阱与挑战
    • 严格的监管要求
    • 潜在不利影响的风险
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• VEGF-A拮抗剂
• TNF-α抑制剂

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 黄斑部病变
• 糖尿病性视网膜病变
• 葡萄膜炎
• 其他适应症

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• Janssen Pharmaceuticals (Johnson & Johnson)
• F-Hoffman La Roche Ltd.
• Oxurion NV
• Novartis AG
• MeiraGTx Limited
• Regeneron Pharmaceuticals Inc.
• OncoGene Pharmaceuticals
• SemaThera Inc.

The Retinal Biologics Market size will grow at 8.2% CAGR during 2024-2032, driven by the increasing prevalence of retinal disorders. According to Ocular Therapeutix, an estimated 401.6 million people worldwide are affected by various forms of retinal disease. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are becoming more common, largely due to an aging global population and the rising incidence of diabetes and hypertension. Retinal biologics, with their advanced therapeutic capabilities offer targeted and efficient treatment options.

Innovations in biotechnology have enabled the creation of novel treatments that specifically target the underlying causes of retinal diseases. These new biologic therapies offer improved efficacy and safety profiles compared to traditional treatments, providing significant benefits for patients with conditions like diabetic retinopathy. Ongoing research and clinical trials continue to address unmet medical needs and expand the therapeutic landscape.

The retinal biologics industry is classified based on drug class, indication, distribution channel, and region.

The TNF-a inhibitors segment will gain traction through 2032, as they work by blocking the tumor necrosis factor-alpha (TNF-a) protein. These inhibitors have shown significant efficacy in reducing inflammation and halting the progression of diseases such as diabetic retinopathy and uveitis. The effectiveness of TNF-a inhibitors in preserving vision and preventing further retinal damage makes them a valuable addition to the therapeutic arsenal for retinal disorders.

The online pharmacies segment will grow rapidly through 2032, owing to the easy access to a wide range of biologic treatments, including those for retinal disorders, often at competitive prices. The convenience of home delivery, coupled with the ability to consult healthcare professionals online, is making online pharmacies an attractive option for patients. The COVID-19 pandemic has accelerated the shift towards online purchasing, with many patients opting for digital channels to avoid in-person visits to pharmacies. This trend is expected to continue as more consumers become comfortable with online shopping for their healthcare needs.

Europe retinal biologics market size will expand at a steady pace through 2032, driven by a well-established healthcare infrastructure and high medical spending. The region's aging population is contributing to an increasing prevalence of retinal disorders, creating a substantial demand for effective treatments. Countries such as Germany, the United Kingdom, France, and Italy are at the forefront of adopting advanced retinal biologics, supported by strong regulatory frameworks and government initiatives aimed at improving eye health. Additionally, Europe is home to several leading pharmaceutical companies and research institutions that are actively involved in the development and commercialization of retinal biologics.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of retinal diseases
    • 3.2.1.2 Rising research & development activities related to retinal biologics
    • 3.2.1.3 Advancements in biologic therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Risk of potential adverse effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 VEGF-A antagonist
• 5.3 TNF-a inhibitor

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Macular degeneration
• 6.3 Diabetic retinopathy
• 6.4 Uveitis
• 6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 Janssen Pharmaceuticals (Johnson & Johnson)
• 9.4 F-Hoffman La Roche Ltd.
• 9.5 Oxurion NV
• 9.6 Novartis AG
• 9.7 MeiraGTx Limited
• 9.8 Regeneron Pharmaceuticals Inc.
• 9.9 OncoGene Pharmaceuticals
• 9.10 SemaThera Inc.